Neoadjuvant immunotherapy: Results in melanoma show promise and pave the way for other solid tumors

It is astonishing to consider that it was only 10 years ago that the first immune checkpoint blockade inhibitor garnered Food and Drug Administration approval. Modern immunotherapy began as single-agent therapy in patients with widely metastatic disease in just a few types of cancer, whereas today, hundreds of different agents targeting various aspects of the […]

Beth A. Helmink, MD, PhD, Judy C. Boughey, MD, FACS, Christina L. Roland, MD, MS, FACS

April 1, 2021